Sygnature Discovery, a provider of integrated drug discovery services, and Cyprotex Discovery Ltd., a specialist ADME-Tox/PK preclinical discovery and development CRO, have entered into an extension of their strategic alliance for a further two years. The companies will expand their collaborative sales and marketing initiative to provide a fully-integrated discovery chemistry/ADME-Tox/DMPK service to accelerate their clients’ drug discovery projects into development.

Dr Anthony Baxter, chief executive officer at Cyprotex, said, “We are delighted to have extended our strategic alliance with Sygnature. The quality of their work and their desire to help customers achieve scientific success has enabled both of us to form a formidable combined offering in medicinal chemistry-driven integrated drug discovery and ADME-Tox services.”

Since the alliance began two years ago, both companies have expanded. Cyprotex acquired Apredica, an ADME-Tox specialist CRO, and the assets of Cellumen, including proprietary high content toxicology assays under the Cellciphr brand. Sygnature recently formed a strategic alliance with Saretius Ltd., a preclinical experimental services company offering models in pain, CNS disorders, inflammatory and metabolic diseases.